Page 43 - Read Online

Benhammou et al. Hepatoma Res 2020;6:35 I http://dx.doi.org/10.20517/2394-5079.2020.16 Page 15 of 15

114. Zhu L, Shan LJ, Liu YJ, Chen D, Xiao XG, et al. Ursodeoxycholic acid induces apoptosis of hepatocellular carcinoma cells in vitro. J Dig
Dis 2014;15:684-93.
115. Li J, Sung CY, Lee N, Ni Y, Pihlajamäki J, et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in
mice. Proc Natl Acad Sci U S A 2016;113:E1306-15.
116. Zhang HL, Yu LX, Yang W, Tang L, Lin Y, et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic
inflammation and hepatocarcinogenesis in rats. J Hepatol 2012;57:803-12.
117. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through
senescence secretome. Nature 2013;499:97-101.
118. Tokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty
liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol
2011;46:1230-7.
119. Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop
hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9:428-33.
120. Kawada N, Imanaka K, Kawaguchi T, Tamai C, Ishihara R, et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic
steatohepatitis. J Gastroenterol 2009;44:1190-4.
121. Pais R, Fartoux L, Goumard C, Scatton O, Wendum D, et al. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in
patients undergoing liver resection over a 20-year period. Aliment Pharmacol Ther 2017;46:856-63.
122. Grohmann M, Wiede F, Dodd GT, Gurzov EN, Ooi GJ, et al. Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC. Cell
2018;175:1289-306.e20.
123. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.
Gastroenterology 2006;130:1117-28.
124. He G, Yu GY, Temkin V, Ogata H, Kuntzen C, et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by
preventing oxidative stress-driven STAT3 activation. Cancer Cell 2010;17:286-97.
125. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018
practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-50.
126. European Association for the Study of the Liver. Corrigendum to “EASL Clinical Practice Guidelines: Management of hepatocellular
carcinoma” [J Hepatol 69 (2018) 182-236]. J Hepatol 2019;70:817.
127. Del Poggio P, Olmi S, Ciccarese F, Di Marco M, Rapaccini GL, et al. Factors that affect efficacy of ultrasound surveillance for early stage
hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014;12:1927-33.e2.
128. Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma
surveillance in patients with cirrhosis. Aliment Pharmacol Ther 2017;45:169-77.
129. Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, et al. Editorial: ultrasound surveillance of hepatocellular carcinoma in the 21st
century - authors’ reply. Aliment Pharmacol Ther 2017;45:562-63.
130. Zhang E, Wartelle-Bladou C, Lepanto L, Lachaine J, Cloutier G, et al. Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur
Radiol 2015;25:3282-94.
131. Khatri G, Pedrosa I, Ananthakrishnan L, de Leon AD, Fetzer DT, et al. Abbreviated-protocol screening MRI vs. complete-protocol
diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: an equivalence study using LI-RADS v2018. J Magn
Reson Imaging 2020;51:415-25.
132. Leerapun A, Suravarapu SV, Bida JP, Clark RJ, Sanders EL, et al. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the
diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol 2007;5:394-402.
133. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of
primary hepatocellular carcinoma. N Engl J Med 1984;310:1427-31.
134. Best J, Bechmann LP, Sowa JP, Sydor S, Dechêne A, et al. GALAD score detects early hepatocellular carcinoma in an international
cohort of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2020;18:728-35.e4.
135. Loomba R, Lim JK, Patton H, El-Serag HB. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in
patients with nonalcoholic fatty liver disease: expert review. Gastroenterology 2020;158:1822-30.
136. Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, et al. Association of nonalcoholic fatty liver disease (NAFLD) with
hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015;62:1723-30.
137. Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a
multidisciplinary team. J Hepatol 2014;60:110-7.
138. Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, et al. Difference in malignancies of chronic liver disease due to non-alcoholic
fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol Res 2012;42:264-72.
139. Shen JH, Li YL, Li D, Wang NN, Jing L, et al. The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis. J Lipid
Res 2015;56:167-75.
140. Vespasiani-Gentilucci U, Gallo P, Dell’Unto C, Volpentesta M, Antonelli-Incalzi R, et al. Promoting genetics in non-alcoholic fatty liver
disease: combined risk score through polymorphisms and clinical variables. World J Gastroenterol 2018;24:4835-45.